

# Maj Vinberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5258881/publications.pdf>

Version: 2024-02-01

233  
papers

8,824  
citations

50170

46  
h-index

60497

81  
g-index

256  
all docs

256  
docs citations

256  
times ranked

8852  
citing authors

#	ARTICLE	IF	CITATIONS
1	Socio-economic functioning in patients with bipolar disorder and their unaffected siblings – results from a nation-wide population-based longitudinal study. <i>Psychological Medicine</i> , 2023, 53, 706-713.	2.7	18
2	Association between lifetime and recent stressful life events and the early course and psychopathology in patients with newly diagnosed bipolar disorder, first-degree unaffected relatives and healthy controls: Cross-sectional results from a prospective study. <i>Bipolar Disorders</i> , 2022, 24, 59-68.	1.1	2
3	Physical health status in first-degree relatives of patients with bipolar disorder, a systematic review. <i>Nordic Journal of Psychiatry</i> , 2022, 76, 433-441.	0.7	1
4	Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. <i>Brain, Behavior, and Immunity</i> , 2022, 101, 93-135.	2.0	670
5	Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2022, 300, 449-461.	2.0	34
6	At the Core of Depression: A Diagnostic Interview of the Core Features of Depression. <i>Psychopathology</i> , 2022, 55, 219-225.	1.1	1
7	Discriminating between patients with unipolar disorder, bipolar disorder, and healthy control individuals based on voice features collected from naturalistic smartphone calls. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 255-267.	2.2	2
8	Socio-economic status and functioning in patients newly diagnosed with bipolar disorder and their unaffected siblings - Results from a cross-sectional clinical study. <i>Journal of Affective Disorders</i> , 2022, 310, 404-411.	2.0	7
9	Neural underpinnings of emotion regulation subgroups in remitted patients with recently diagnosed bipolar disorder. <i>European Neuropsychopharmacology</i> , 2022, 60, 7-18.	0.3	6
10	Differential trajectory of cognitive functions in neurocognitive subgroups of newly diagnosed patients with bipolar disorder and their unaffected first-degree relatives – A longitudinal study. <i>Journal of Affective Disorders</i> , 2022, 311, 115-125.	2.0	3
11	Affective disorders: eliminate Warning signs and Restore functioning – AWARE – a randomised controlled multimodule intervention study, presentation of design and intervention. <i>BMJ Open</i> , 2022, 12, e058839.	0.8	0
12	Trajectory of aberrant reward processing in patients with bipolar disorder – A longitudinal fMRI study. <i>Journal of Affective Disorders</i> , 2022, 312, 235-244.	2.0	4
13	Effect of Action-Based Cognitive Remediation on cognitive impairment in patients with remitted bipolar disorder: A randomized controlled trial. <i>Bipolar Disorders</i> , 2021, 23, 487-499.	1.1	31
14	Mood, activity, and sleep measured via daily smartphone-based self-monitoring in young patients with newly diagnosed bipolar disorder, their unaffected relatives and healthy control individuals. <i>European Child and Adolescent Psychiatry</i> , 2021, 30, 1209-1221.	2.8	6
15	Reduced frontostriatal response to expected value and reward prediction error in remitted monozygotic twins with mood disorders and their unaffected high-risk co-twins. <i>Psychological Medicine</i> , 2021, 51, 1637-1646.	2.7	9
16	Hippocampal subfield morphology in monozygotic twins discordant for affective disorders. <i>Neuropsychopharmacology</i> , 2021, 46, 561-568.	2.8	4
17	Cognitive processing of infant stimuli in pregnant women with and without affective disorders and the association to postpartum depression. <i>European Neuropsychopharmacology</i> , 2021, 42, 97-109.	0.3	6
18	Daily mobility patterns in patients with bipolar disorder and healthy individuals. <i>Journal of Affective Disorders</i> , 2021, 278, 413-422.	2.0	16

#	ARTICLE	IF	CITATIONS
19	A nationwide population-based longitudinal study mapping psychiatric disorders during lifetime in siblings to patients with bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 284-293.	2.2	11
20	Residual Anxiety in Patients with Bipolar Disorder in Full or Partial Remission: Metacognitive Beliefs and Neurocognitive Function. <i>Cognitive Therapy and Research</i> , 2021, 45, 179-189.	1.2	1
21	The impact of the trajectory of bipolar disorder on global cognitive function: A one-year clinical prospective case-control study. <i>Journal of Affective Disorders</i> , 2021, 278, 189-198.	2.0	10
22	Neurocognitive heterogeneity in patients with bipolar disorder and their unaffected relatives: associations with emotional cognition. <i>Psychological Medicine</i> , 2021, 51, 668-679.	2.7	26
23	Suicidal behaviour and bipolar disorder. , 2021, , 293-300.		0
24	Brain-derived neurotrophic factor levels in newly diagnosed patients with bipolar disorder, their unaffected first-degree relatives and healthy controls. <i>BJPsych Open</i> , 2021, 7, e55.	0.3	9
25	P.319 Cognitive predictors of mood episodes in patients newly diagnosed with bipolar disorder. <i>European Neuropsychopharmacology</i> , 2021, 44, S52-S53.	0.3	0
26	Intrauterine testosterone exposure and depression risk in opposite-sex and same-sex twins, a Danish register study. <i>Psychological Medicine</i> , 2021, , 1-6.	2.7	0
27	Peripheral inflammatory biomarkers define biotypes of bipolar depression. <i>Molecular Psychiatry</i> , 2021, 26, 3395-3406.	4.1	19
28	A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions. <i>Journal of Affective Disorders</i> , 2021, 282, 160-164.	2.0	24
29	Affective and non-affective cognition in patients with bipolar disorder type I and type II in full or partial remission: Associations with familial risk. <i>Journal of Affective Disorders</i> , 2021, 283, 207-215.	2.0	4
30	Associations between the cortisol awakening response and patient-evaluated stress and mood instability in patients with bipolar disorder: an exploratory study. <i>International Journal of Bipolar Disorders</i> , 2021, 9, 8.	0.8	7
31	A nation-wide population-based longitudinal study mapping physical diseases in patients with bipolar disorder and their siblings. <i>Journal of Affective Disorders</i> , 2021, 282, 18-25.	2.0	22
32	Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression. <i>Advances in Therapy</i> , 2021, 38, 2795-2820.	1.3	19
33	Impact of modification to DSM-5 criterion A for hypomania/mania in newly diagnosed bipolar patients: findings from the prospective BIO study. <i>International Journal of Bipolar Disorders</i> , 2021, 9, 14.	0.8	4
34	Higher systemic oxidatively generated DNA and RNA damage in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. <i>Free Radical Biology and Medicine</i> , 2021, 168, 226-233.	1.3	12
35	Peripheral Inflammatory Biomarkers Define Biotypes of Bipolar Depression. <i>Biological Psychiatry</i> , 2021, 89, S156.	0.7	2
36	Prevalences of comorbid anxiety disorder and daily smartphone-based self-reported anxiety in patients with newly diagnosed bipolar disorder. <i>Evidence-Based Mental Health</i> , 2021, 24, 137-144.	2.2	2

#	ARTICLE	IF	CITATIONS
37	Affective disorders impact prevalence of Flavonifactor and abundance of Christensenellaceae in gut microbiota. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 110, 110300.	2.5	15
38	Automatically Generated Smartphone Data in Young Patients With Newly Diagnosed Bipolar Disorder and Healthy Controls. <i>Frontiers in Psychiatry</i> , 2021, 12, 559954.	1.3	3
39	Emotional cognition subgroups in mood disorders: Associations with familial risk. <i>European Neuropsychopharmacology</i> , 2021, 51, 71-83.	0.3	9
40	A nation-wide population-based longitudinal study on life expectancy and cause specific mortality in patients with bipolar disorder and their siblings. <i>Journal of Affective Disorders</i> , 2021, 294, 472-476.	2.0	12
41	Affective episodes in recently diagnosed patients with bipolar disorder associated with altered working memory-related prefrontal cortex activity: A longitudinal fMRI study. <i>Journal of Affective Disorders</i> , 2021, 295, 647-656.	2.0	8
42	Effect of specialised versus generalised outpatient treatment for bipolar disorder: the CAG Bipolar trial - study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e048821.	0.8	3
43	Voice analyses using smartphone-based data in patients with bipolar disorder, unaffected relatives and healthy control individuals, and during different affective states. <i>International Journal of Bipolar Disorders</i> , 2021, 9, 38.	0.8	7
44	Physical Health Profile and Associated Behavior During the COVID-19 Pandemic in Patients With Bipolar Disorder. <i>Frontiers in Psychiatry</i> , 2021, 12, 759694.	1.3	5
45	P.0717 Differential trajectory of cognitive functions in neurocognitive subgroups of newly diagnosed patients with bipolar disorder and their unaffected first-degree relatives. <i>European Neuropsychopharmacology</i> , 2021, 53, S524-S525.	0.3	0
46	P.0077 Higher systemic oxidatively generated DNA and RNA damage in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. <i>European Neuropsychopharmacology</i> , 2021, 53, S54-S55.	0.3	0
47	The effect of smartphone-based monitoring on illness activity in bipolar disorder: the MONARCA II randomized controlled single-blinded trial. <i>Psychological Medicine</i> , 2020, 50, 838-848.	2.7	75
48	Aberrant cognition in newly diagnosed patients with bipolar disorder and their unaffected relatives. <i>Psychological Medicine</i> , 2020, 50, 1808-1819.	2.7	22
49	Are remitted affective disorders and familial risk of affective disorders associated with metabolic syndrome, inflammation and oxidative stress? â€“ a monozygotic twin study. <i>Psychological Medicine</i> , 2020, 50, 1736-1745.	2.7	12
50	Automatically generated smartphone data and subjective stress in healthy individuals â€“ a pilot study. <i>Nordic Journal of Psychiatry</i> , 2020, 74, 293-300.	0.7	2
51	P.298 Emotional cognition heterogeneity in patients with mood disorders and clinical implication. <i>European Neuropsychopharmacology</i> , 2020, 40, S170-S171.	0.3	0
52	Bipolar disorders. <i>Lancet</i> , The, 2020, 396, 1841-1856.	6.3	419
53	Searching for the Needles in a Haystack; Is It Needless? The Search for Peripheral Biomarkers in Psychiatry. <i>Frontiers in Psychiatry</i> , 2020, 11, 689.	1.3	3
54	Daily self-reported and automatically generated smartphone-based sleep measurements in patients with newly diagnosed bipolar disorder, unaffected first-degree relatives and healthy control individuals. <i>Evidence-Based Mental Health</i> , 2020, 23, 146-153.	2.2	6

#	ARTICLE	IF	CITATIONS
55	Impact of pretreatment interhemispheric hippocampal asymmetry on improvement in verbal learning following erythropoietin treatment in mood disorders: a randomized controlled trial. <i>Journal of Psychiatry and Neuroscience</i> , 2020, 45, 198-205.	1.4	5
56	Validity and characteristics of patient-evaluated adherence to medication via smartphones in patients with bipolar disorder: exploratory reanalyses on pooled data from the MONARCA I and II trials. <i>Evidence-Based Mental Health</i> , 2020, 23, 2-7.	2.2	4
57	The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. <i>Bipolar Disorders</i> , 2020, 22, 831-840.	1.1	40
58	S100B and brain derived neurotrophic factor in monozygotic twins with, at risk of and without affective disorders. <i>Journal of Affective Disorders</i> , 2020, 274, 726-732.	2.0	4
59	Transcranial pulsed electromagnetic fields for treatment-resistant depression: A multicenter 8-week single-arm cohort study. <i>European Psychiatry</i> , 2020, 63, e18.	0.1	9
60	Hypomania/Mania by DSM-5 definition based on daily smartphone-based patient-reported assessments. <i>Journal of Affective Disorders</i> , 2020, 264, 272-278.	2.0	6
61	Misinformed, misconducted, misguided and misrepresented meta-analyses. The use of antidepressants (AD) in major depressive disorders (MDD). <i>Bipolar Disorders</i> , 2020, 22, 862-863.	1.1	0
62	Mood instability in patients with newly diagnosed bipolar disorder, unaffected relatives, and healthy control individuals measured daily using smartphones. <i>Journal of Affective Disorders</i> , 2020, 271, 336-344.	2.0	23
63	Abnormal prefrontal cortex processing of reward prediction errors in recently diagnosed patients with bipolar disorder and their unaffected relatives. <i>Bipolar Disorders</i> , 2020, 22, 849-859.	1.1	4
64	Sleep and physical activity in patients with newly diagnosed bipolar disorder in remission, their first-degree unaffected relatives and healthy controls. <i>International Journal of Bipolar Disorders</i> , 2020, 8, 16.	0.8	10
65	Smartphone-based activity measurements in patients with newly diagnosed bipolar disorder, unaffected relatives and control individuals. <i>International Journal of Bipolar Disorders</i> , 2020, 8, 32.	0.8	17
66	Development and implementation of guidelines for the management of depression: a systematic review. <i>Bulletin of the World Health Organization</i> , 2020, 98, 683-697H.	1.5	25
67	High-sensitive C-reactive protein and homocysteine levels in patients with newly diagnosed bipolar disorder, their first-degree relatives, and healthy control persons—Results from a clinical study. <i>European Psychiatry</i> , 2020, 63, e103.	0.1	2
68	Patient-evaluated cognitive function measured with smartphones and the association with objective cognitive function, perceived stress, quality of life and function capacity in patients with bipolar disorder. <i>International Journal of Bipolar Disorders</i> , 2020, 8, 31.	0.8	5
69	Is aberrant affective cognition an endophenotype for affective disorders? — A monozygotic twin study. <i>Psychological Medicine</i> , 2019, 49, 987-996.	2.7	12
70	A randomized placebo-controlled trial examining the effects of escitalopram on neuroticism and state anxiety in a nonclinical sample. <i>Human Psychopharmacology</i> , 2019, 34, e2711.	0.7	1
71	The validity of daily patient-reported anxiety measured using smartphones and the association with stress, quality of life and functioning in patients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2019, 257, 100-107.	2.0	9
72	Whole-Brain Exploratory Analysis of Functional Task Response Following Erythropoietin Treatment in Mood Disorders: A Supervised Machine Learning Approach. <i>Frontiers in Neuroscience</i> , 2019, 13, 1246.	1.4	2

#	ARTICLE	IF	CITATIONS
73	Differences in mood instability in patients with bipolar disorder type I and II: a smartphone-based study. <i>International Journal of Bipolar Disorders</i> , 2019, 7, 5.	0.8	29
74	Metabolic profile in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. <i>International Journal of Bipolar Disorders</i> , 2019, 7, 8.	0.8	39
75	Is smartphone-based mood instability associated with stress, quality of life, and functioning in bipolar disorder?. <i>Bipolar Disorders</i> , 2019, 21, 611-620.	1.1	32
76	Thirty-year cardiovascular risk in patients with newly diagnosed bipolar disorder and their healthy first-degree relatives. <i>European Neuropsychopharmacology</i> , 2019, 29, S347-S348.	0.3	1
77	Hormones, Emotional processing and prepartum Attachment in Pregnant women with Affective Disorders (HEAPAD). <i>European Neuropsychopharmacology</i> , 2019, 29, S382.	0.3	0
78	The association between mixed symptoms, irritability and functioning measured using smartphones in bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 443-453.	2.2	12
79	P.4.08 Metabolic syndrome, inflammation and oxidative stress as potential risk factors for affective disorders – a twin study. <i>European Neuropsychopharmacology</i> , 2019, 29, S706-S707.	0.3	0
80	P.654 Central oxidative stress of RNA damage in patients with bipolar disorder and healthy control individuals. A prospective longitudinal case-control study. <i>European Neuropsychopharmacology</i> , 2019, 29, S444.	0.3	0
81	P.357 S100B and brain derived neurotrophic factor in monozygotic twins with, at risk of and without affective disorders. <i>European Neuropsychopharmacology</i> , 2019, 29, S255.	0.3	0
82	Cerebrospinal fluid oxidative stress metabolites in patients with bipolar disorder and healthy controls: a longitudinal case-control study. <i>Translational Psychiatry</i> , 2019, 9, 325.	2.4	31
83	The BDNF Val66Met Polymorphism Has No Effect on Encoding-Related Hippocampal Response But Influences Recall in Remitted Patients With Bipolar Disorder. <i>Frontiers in Psychiatry</i> , 2019, 10, 845.	1.3	2
84	Emotional Mental Imagery Abnormalities in Monozygotic Twins With, at High-Risk of, and Without Affective Disorders: Present in Affected Twins in Remission but Absent in High-Risk Twins. <i>Frontiers in Psychiatry</i> , 2019, 10, 801.	1.3	5
85	The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders. <i>European Neuropsychopharmacology</i> , 2019, 29, 137-146.	0.3	19
86	Neural response during emotion regulation in monozygotic twins at high familial risk of affective disorders. <i>NeuroImage: Clinical</i> , 2019, 21, 101598.	1.4	34
87	A multisystem composite biomarker as a preliminary diagnostic test in bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 227-236.	2.2	23
88	Objective smartphone data as a potential diagnostic marker of bipolar disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 119-128.	1.3	66
89	Remitted affective disorders and high familial risk of affective disorders associate with aberrant intestinal microbiota. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 174-184.	2.2	35
90	Thirty-year cardiovascular risk score in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 651-662.	1.3	31

#	ARTICLE	IF	CITATIONS
91	Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. <i>Brain, Behavior, and Immunity</i> , 2019, 75, 112-118.	2.0	103
92	Hair cortisol in newly diagnosed bipolar disorder and unaffected first-degree relatives. <i>Psychoneuroendocrinology</i> , 2019, 99, 183-190.	1.3	23
93	Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative. <i>International Journal of Bipolar Disorders</i> , 2019, 7, 20.	0.8	41
94	Neural response to emotional faces in monozygotic twins: association with familial risk of affective disorders. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, 277-286.	1.4	4
95	Increased sensitivity to positive social stimuli in monozygotic twins at risk of bipolar vs. unipolar disorder. <i>Journal of Affective Disorders</i> , 2018, 232, 212-218.	2.0	10
96	Leukocytes in peripheral blood in patients with bipolar disorder – Trait and state alterations and association with levels of cytokines and C-reactive protein. <i>Psychiatry Research</i> , 2018, 261, 383-390.	1.7	12
97	Glycogen synthase kinase-3 $\beta$ activity and cognitive functioning in patients with bipolar I disorder. <i>European Neuropsychopharmacology</i> , 2018, 28, 361-368.	0.3	4
98	Risk for affective disorders is associated with greater prefrontal gray matter volumes: A prospective longitudinal study. <i>NeuroImage: Clinical</i> , 2018, 17, 786-793.	1.4	13
99	Erythropoietin as an add-on treatment for cognitive side effects of electroconvulsive therapy: a study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 234.	0.7	7
100	Is negative self-referent bias an endophenotype for depression? An fMRI study of emotional self-referent words in twins at high vs. low risk of depression. <i>Journal of Affective Disorders</i> , 2018, 226, 267-273.	2.0	10
101	Risk of recurrence after a single manic or mixed episode – a systematic review and meta-analysis. <i>Bipolar Disorders</i> , 2018, 20, 9-17.	1.1	26
102	Substance use among Danish psychiatric patients: a cross-sectional study. <i>Nordic Journal of Psychiatry</i> , 2018, 72, 130-136.	0.7	11
103	Internet use by older adults with bipolar disorder: international survey results. <i>International Journal of Bipolar Disorders</i> , 2018, 6, 20.	0.8	13
104	Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 611.	0.7	16
105	Mogens Schou (1918–2005): a scientist, a doctor and a lithium champion. <i>Bipolar Disorders</i> , 2018, 20, 680-682.	1.1	0
106	Clinical Characteristics, Life Adversities and Personality Traits in Monozygotic Twins With, at Risk of and Without Affective Disorders. <i>Frontiers in Psychiatry</i> , 2018, 9, 401.	1.3	11
107	Effect of action-based cognitive remediation on cognition and neural activity in bipolar disorder: study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 487.	0.7	18
108	Does S100B have a potential role in affective disorders? A literature review. <i>Nordic Journal of Psychiatry</i> , 2018, 72, 462-470.	0.7	16

#	ARTICLE	IF	CITATIONS
109	Ketogenic diet as a metabolic therapy for mood disorders: Evidence and developments. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 94, 11-16.	2.9	102
110	Towards a biomarker model for cognitive improvement: No change in memory-related prefrontal engagement following a negative cognitive remediation trial in bipolar disorder. <i>Journal of Psychopharmacology</i> , 2018, 32, 1075-1085.	2.0	14
111	Neural correlates of improved recognition of happy faces after erythropoietin treatment in bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 336-347.	2.2	5
112	Effects of erythropoietin on body composition and fat glucose metabolism in patients with affective disorders. <i>Acta Neuropsychiatrica</i> , 2018, 30, 342-349.	1.0	10
113	Influences of patient informed cognitive complaints on activities of daily living in patients with bipolar disorder. An exploratory cross-sectional study. <i>Psychiatry Research</i> , 2017, 249, 268-274.	1.7	19
114	Differences in neural and cognitive response to emotional faces in middle-aged dizygotic twins at familial risk of depression. <i>Psychological Medicine</i> , 2017, 47, 2345-2357.	2.7	11
115	Sexual distress and quality of life among women with bipolar disorder. <i>International Journal of Bipolar Disorders</i> , 2017, 5, 29.	0.8	18
116	The catechol methyltransferase ( <i>COMT</i> ) Val158Met genotype modulates working memory-related dorsolateral prefrontal response and performance in bipolar disorder. <i>Bipolar Disorders</i> , 2017, 19, 214-224.	1.1	54
117	The search for neuroimaging and cognitive endophenotypes: A critical systematic review of studies involving unaffected first-degree relatives of individuals with bipolar disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 73, 1-22.	2.9	85
118	Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders. <i>European Neuropsychopharmacology</i> , 2017, 27, 1153-1162.	0.3	49
119	Increased blood BDNF in healthy individuals with a family history of depression. <i>Psychiatry Research</i> , 2017, 256, 176-179.	1.7	16
120	International multi-site survey on the use of online support groups in bipolar disorder. <i>Nordic Journal of Psychiatry</i> , 2017, 71, 473-476.	0.7	4
121	The Bipolar Illness Onset study: research protocol for the BIO cohort study. <i>BMJ Open</i> , 2017, 7, e015462.	0.8	119
122	Differences in clinical presentation between bipolar I and II disorders in the early stages of bipolar disorder: A naturalistic study. <i>Journal of Affective Disorders</i> , 2017, 208, 521-527.	2.0	26
123	Personalized medicine in psychiatry. <i>Nordic Journal of Psychiatry</i> , 2017, 71, 12-19.	0.7	46
124	Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study. <i>Journal of Affective Disorders</i> , 2017, 207, 114-120.	2.0	110
125	Ability to perform Activities of Daily Living among patients with bipolar disorder in remission. <i>Edorium Journal of Disability and Rehabilitation</i> , 2017, 3, 3.	0.3	5
126	Effects of erythropoietin on memory-relevant neurocircuitry activity and recall in mood disorders. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 249-259.	2.2	27



#	ARTICLE	IF	CITATIONS
127	Glycogen synthase kinase-3 $\beta$ in patients with bipolar I disorder: results from a prospective study. <i>Bipolar Disorders</i> , 2016, 18, 334-341.	1.1	8
128	Brain-derived neurotrophic factor, impaired glucose metabolism, and bipolar disorder course. <i>Bipolar Disorders</i> , 2016, 18, 373-378.	1.1	20
129	Increased DNA and RNA damage by oxidation in patients with bipolar I disorder. <i>Translational Psychiatry</i> , 2016, 6, e867-e867.	2.4	42
130	Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project. <i>CNS Spectrums</i> , 2016, 21, 362-366.	0.7	31
131	Neural correlates of improved executive function following erythropoietin treatment in mood disorders. <i>Psychological Medicine</i> , 2016, 46, 1679-1691.	2.7	34
132	Glycogen Synthase Kinase-3 $\beta$ : Variation over Time and the Possible Association with Mood and Cognition in Healthy Individuals. <i>Neuropsychobiology</i> , 2016, 73, 108-115.	0.9	5
133	No effect of escitalopram versus placebo on brain-derived neurotrophic factor in healthy individuals: a randomised trial. <i>Acta Neuropsychiatrica</i> , 2016, 28, 101-109.	1.0	6
134	A peripheral composite proteomic and gene expression biomarker related to diagnosis and affective state in rapid cycling bipolar disorder. <i>European Psychiatry</i> , 2016, 33, S123-S123.	0.1	0
135	Unaffected twins discordant for affective disorders show changes in anterior callosal white matter microstructure. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 441-451.	2.2	6
136	The effect of erythropoietin on cognition in affective disorders – Associations with baseline deficits and change in subjective cognitive complaints. <i>European Neuropsychopharmacology</i> , 2016, 26, 1264-1273.	0.3	45
137	Online information seeking by patients with bipolar disorder: results from an international multisite survey. <i>International Journal of Bipolar Disorders</i> , 2016, 4, 17.	0.8	35
138	Discrete neurocognitive subgroups in fully or partially remitted bipolar disorder: Associations with functional abilities. <i>Journal of Affective Disorders</i> , 2016, 205, 378-386.	2.0	110
139	Internet use by patients with bipolar disorder: Results from an international multisite survey. <i>Psychiatry Research</i> , 2016, 242, 388-394.	1.7	36
140	Voice analysis as an objective state marker in bipolar disorder. <i>Translational Psychiatry</i> , 2016, 6, e856-e856.	2.4	167
141	Behavioral activities collected through smartphones and the association with illness activity in bipolar disorder. <i>International Journal of Methods in Psychiatric Research</i> , 2016, 25, 309-323.	1.1	113
142	Effect of recombinant erythropoietin on inflammatory markers in patients with affective disorders: A randomised controlled study. <i>Brain, Behavior, and Immunity</i> , 2016, 57, 53-57.	2.0	22
143	Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. <i>Bipolar Disorders</i> , 2016, 18, 89-101.	1.1	153
144	Effect of escitalopram versus placebo on GR $\alpha$ messenger RNA expression in peripheral blood cells of healthy individuals with a family history of depression – a secondary outcome analysis from the randomized AGENDA trial. <i>Nordic Journal of Psychiatry</i> , 2016, 70, 297-302.	0.7	4

#	ARTICLE	IF	CITATIONS
145	Cytokines, brain-derived neurotrophic factor and C-reactive protein in bipolar I disorder – Results from a prospective study. <i>Journal of Affective Disorders</i> , 2016, 197, 167-174.	2.0	67
146	Impaired down-regulation of negative emotion in self-referent social situations in bipolar disorder: A pilot study of a novel experimental paradigm. <i>Psychiatry Research</i> , 2016, 238, 318-325.	1.7	23
147	The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative Project. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 153-159.	1.1	35
148	State-related differences in the level of psychomotor activity in patients with bipolar disorder – Continuous heart rate and movement monitoring. <i>Psychiatry Research</i> , 2016, 237, 166-174.	1.7	27
149	Peripheral blood brain-derived neurotrophic factor in bipolar disorder: a comprehensive systematic review and meta-analysis. <i>Molecular Psychiatry</i> , 2016, 21, 216-228.	4.1	120
150	Healthy co-twins of patients with affective disorders show reduced risk-related activation of the insula during a monetary gambling task. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, 38-47.	1.4	7
151	Targeting Treatments to Improve Cognitive Function in Mood Disorder. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1639-e1646.	1.1	37
152	Risk. Impact of having a first-degree relative with affective disorder: a 7-year follow-up study. <i>Danish Medical Journal</i> , 2016, 63, .	0.5	0
153	Daily electronic self-monitoring in bipolar disorder using smartphones – the MONARCA I trial: a randomized, placebo-controlled, single-blind, parallel group trial. <i>Psychological Medicine</i> , 2015, 45, 2691-2704.	2.7	152
154	Smartphone data as an electronic biomarker of illness activity in bipolar disorder. <i>Bipolar Disorders</i> , 2015, 17, 715-728.	1.1	131
155	The Effect of Recombinant Erythropoietin on Plasma Brain Derived Neurotrophic Factor Levels in Patients with Affective Disorders: A Randomised Controlled Study. <i>PLoS ONE</i> , 2015, 10, e0127629.	1.1	18
156	Effects of Short-Term Cognitive Remediation on Cognitive Dysfunction in Partially or Fully Remitted Individuals with Bipolar Disorder: Results of a Randomised Controlled Trial. <i>PLoS ONE</i> , 2015, 10, e0127955.	1.1	91
157	Electronic monitoring of psychomotor activity as a supplementary objective measure of depression severity. <i>Nordic Journal of Psychiatry</i> , 2015, 69, 118-125.	0.7	16
158	The Prevalence, Measurement, and Treatment of the Cognitive Dimension/Domain in Major Depressive Disorder. <i>CNS Drugs</i> , 2015, 29, 577-589.	2.7	113
159	Reduced mRNA Expression of PTDGDS in Peripheral Blood Mononuclear Cells of Rapid-Cycling Bipolar Disorder Patients Compared with Healthy Control Subjects. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu101-pyu101.	1.0	22
160	Mood instability in bipolar disorder type I versus type II-continuous daily electronic self-monitoring of illness activity using smartphones. <i>Journal of Affective Disorders</i> , 2015, 186, 342-349.	2.0	50
161	Assessment of subjective and objective cognitive function in bipolar disorder: Correlations, predictors and the relation to psychosocial function. <i>Psychiatry Research</i> , 2015, 229, 565-571.	1.7	67
162	Different neural and cognitive response to emotional faces in healthy monozygotic twins at risk of depression. <i>Psychological Medicine</i> , 2015, 45, 1447-1458.	2.7	32

#	ARTICLE	IF	CITATIONS
163	The Diagnostic Apathia Scale predicts a doseâ€“remission relationship of T-PEMF in treatment-resistant depression. <i>Acta Neuropsychiatrica</i> , 2015, 27, 1-7.	1.0	9
164	Bipolar Patients' Quality of Life in Mixed States: A Preliminary Qualitative Study. <i>Psychopathology</i> , 2015, 48, 192-201.	1.1	11
165	A composite peripheral blood gene expression measure as a potential diagnostic biomarker in bipolar disorder. <i>Translational Psychiatry</i> , 2015, 5, e614-e614.	2.4	58
166	Elevated levels of urinary markers of oxidatively generated DNA and RNA damage in bipolar disorder. <i>Bipolar Disorders</i> , 2015, 17, 257-268.	1.1	51
167	Effects of Erythropoietin on Hippocampal Volume and Memory in Mood Disorders. <i>Biological Psychiatry</i> , 2015, 78, 270-277.	0.7	83
168	Elevated levels of IL-6 and IL-18 in manic and hypomanic states in rapid cycling bipolar disorder patients. <i>Brain, Behavior, and Immunity</i> , 2015, 43, 205-213.	2.0	73
169	Dr Miskowiak and Colleagues Reply. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e835-e836.	1.1	1
170	Daily electronic monitoring of subjective and objective measures of illness activity in bipolar disorder using smartphonesâ€“ the MONARCA II trial protocol: a randomized controlled single-blind parallel-group trial. <i>BMC Psychiatry</i> , 2014, 14, 309.	1.1	82
171	The role of estrogen in bipolar disorder, a review. <i>Nordic Journal of Psychiatry</i> , 2014, 68, 81-87.	0.7	41
172	Dose-remission of pulsating electromagnetic fields as augmentation in therapy-resistant depression: a randomized, double-blind controlled study. <i>Acta Neuropsychiatrica</i> , 2014, 26, 272-279.	1.0	20
173	Serotonin transporter genotype, salivary cortisol, neuroticism and life events: Impact on subsequent psychopathology in healthy twins at high and low risk for affective disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 48, 193-198.	2.5	5
174	Smartphone data as objective measures of bipolar disorder symptoms. <i>Psychiatry Research</i> , 2014, 217, 124-127.	1.7	162
175	Recombinant Human Erythropoietin for Treating Treatment-Resistant Depression: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial. <i>Neuropsychopharmacology</i> , 2014, 39, 1399-1408.	2.8	89
176	Brain Derived Neurotrophic Factor (BDNF) levels as a possible predictor of psychopathology in healthy twins at high and low risk for affective disorder. <i>Psychoneuroendocrinology</i> , 2014, 39, 179-183.	1.3	9
177	Elevated levels of plasma brain derived neurotrophic factor in rapid cycling bipolar disorder patients. <i>Psychoneuroendocrinology</i> , 2014, 47, 199-211.	1.3	45
178	Recombinant Human Erythropoietin to Target Cognitive Dysfunction in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 1347-1355.	1.1	80
179	Cytokines in bipolar disorder vs. healthy control subjects: A systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2013, 47, 1119-1133.	1.5	358
180	P.2.d.033 Erythropoietin as a new treatment for cognitive dysfunction in bipolar disorder?. <i>European Neuropsychopharmacology</i> , 2013, 23, S383.	0.3	0

#	ARTICLE	IF	CITATIONS
181	Cytokines in bipolar disorder: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2013, 144, 16-27.	2.0	229
182	Are variations in whole blood BDNF level associated with the BDNF Val66Met polymorphism in patients with first episode depression?. <i>Psychiatry Research</i> , 2013, 210, 102-108.	1.7	14
183	The effect of prolonged duration of untreated depression on antidepressant treatment outcome. <i>Journal of Affective Disorders</i> , 2013, 145, 42-48.	2.0	85
184	Risk markers for affective disorder, a seven-years follow up study of a twin cohort at low and high risk for affective disorder. <i>Journal of Psychiatric Research</i> , 2013, 47, 565-571.	1.5	22
185	Effects of cognitive remediation on cognitive dysfunction in partially or fully remitted patients with bipolar disorder: study protocol for a randomized controlled trial. <i>Trials</i> , 2013, 14, 378.	0.7	29
186	Daily electronic self-monitoring of subjective and objective symptoms in bipolar disorder—the MONARCA trial protocol (MONitoring, treAtment and pRediCtion of bipolar disorder episodes): a randomised controlled single-blind trial. <i>BMJ Open</i> , 2013, 3, e003353.	0.8	73
187	Designing mobile health technology for bipolar disorder. , 2013, , .		206
188	The Performance of the Revised Major Depression Inventory for Self-Reported Severity of Depression - Implications for the DSM-5 and ICD-11. <i>Psychotherapy and Psychosomatics</i> , 2013, 82, 187-188.	4.0	6
189	Psychostimulants in moderate to severe affective disorder: A systematic review of randomized controlled trials. <i>Nordic Journal of Psychiatry</i> , 2013, 67, 369-382.	0.7	23
190	Impairment of Executive Function and Attention Predicts Onset of Affective Disorder in Healthy High-Risk Twins. <i>Journal of Clinical Psychiatry</i> , 2013, 74, e747-e753.	1.1	34
191	Is there a difference in subjective experience of cognitive function in patients with unipolar disorder versus bipolar disorder?. <i>Nordic Journal of Psychiatry</i> , 2012, 66, 389-395.	0.7	27
192	The effect of escitalopram versus placebo on perceived stress and salivary cortisol in healthy first-degree relatives of patients with depression—a randomised trial. <i>Psychiatry Research</i> , 2012, 200, 354-360.	1.7	19
193	Is there an association between subjective and objective measures of cognitive function in patients with affective disorders?. <i>Nordic Journal of Psychiatry</i> , 2012, 66, 248-253.	0.7	102
194	Differences in psychomotor activity in patients suffering from unipolar and bipolar affective disorder in the remitted or mild/moderate depressive state. <i>Journal of Affective Disorders</i> , 2012, 141, 457-463.	2.0	71
195	Metabolic syndrome in a cohort of affectively ill patients, a naturalistic study. <i>Nordic Journal of Psychiatry</i> , 2012, 66, 142-145.	0.7	6
196	State-related alterations of gene expression in bipolar disorder: a systematic review. <i>Bipolar Disorders</i> , 2012, 14, 684-696.	1.1	38
197	Effect of Chronic Escitalopram versus Placebo on Personality Traits in Healthy First-Degree Relatives of Patients with Depression: A Randomized Trial. <i>PLoS ONE</i> , 2012, 7, e31980.	1.1	13
198	Promoter variants in IL18 are associated with onset of depression in patients previously exposed to stressful-life events. <i>Journal of Affective Disorders</i> , 2012, 136, 134-138.	2.0	47

#	ARTICLE	IF	CITATIONS
199	Psychometric validation and clinical validity of the Minor Melancholia Mood Checklist (MMCL-32). <i>Journal of Affective Disorders</i> , 2012, 137, 79-86.	2.0	1
200	Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression. <i>Psychopharmacology</i> , 2012, 219, 687-698.	1.5	56
201	Subjective experience of cognitive function in affective disorders. <i>European Psychiatry</i> , 2011, 26, 234-234.	0.1	0
202	Escitalopram and Neuroendocrine Response in Healthy First-Degree Relatives to Depressed Patients â€” A Randomized Placebo-Controlled Trial. <i>PLoS ONE</i> , 2011, 6, e21224.	1.1	12
203	From items to syndromes in the Hypomania Checklist (HCL-32): Psychometric validation and clinical validity analysis. <i>Journal of Affective Disorders</i> , 2011, 132, 48-54.	2.0	43
204	A randomized trial of the effect of escitalopram versus placebo on cognitive function in healthy first-degree relatives of patients with depression. <i>Therapeutic Advances in Psychopharmacology</i> , 2011, 1, 133-144.	1.2	8
205	Differences Between Early and Late Onset Adult Depression. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2011, 7, 140-147.	0.6	55
206	Coping Styles in Healthy Individuals at Risk of Affective Disorder. <i>Journal of Nervous and Mental Disease</i> , 2010, 198, 39-44.	0.5	8
207	Does bereavement-related first episode depression differ from other kinds of first depressions?. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2010, 45, 801-808.	1.6	27
208	Hippocampal volume changes in healthy subjects at risk of unipolar depression. <i>Journal of Psychiatric Research</i> , 2010, 44, 655-662.	1.5	70
209	Salivary cortisol in depressed patients versus control persons: A systematic review and meta-analysis. <i>Psychoneuroendocrinology</i> , 2010, 35, 1275-1286.	1.3	247
210	Clinical utility of Standardised Assessment of Personality â€” Abbreviated Scale (SAPAS) among patients with first episode depression. <i>Journal of Affective Disorders</i> , 2010, 127, 199-202.	2.0	27
211	Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. <i>Trials</i> , 2010, 11, 97.	0.7	42
212	Familial Risk for Mood Disorder and the Personality Risk Factor, Neuroticism, Interact in Their Association with Frontolimbic Serotonin 2A Receptor Binding. <i>Neuropsychopharmacology</i> , 2010, 35, 1129-1137.	2.8	49
213	Gender Differences among Patients with a Single Depressive Episode. <i>Psychopathology</i> , 2010, 43, 159-169.	1.1	13
214	The Influence of Comorbid Personality Disorder and Neuroticism on Treatment Outcome in First Episode Depression. <i>Psychopathology</i> , 2010, 43, 197-204.	1.1	41
215	Variations in 5-HTTLPR: Relation to familiar risk of affective disorder, life events, neuroticism and cortisol. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 86-91.	2.5	16
216	No interactions between genetic polymorphisms and stressful life events on outcome of antidepressant treatment. <i>European Neuropsychopharmacology</i> , 2010, 20, 327-335.	0.3	31

#	ARTICLE	IF	CITATIONS
217	Validity of the diagnosis of a single depressive episode in a case register. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2009, 5, 4.	0.6	161
218	The BDNF Val66Met polymorphism: Relation to familiar risk of affective disorder, BDNF levels and salivary cortisol. <i>Psychoneuroendocrinology</i> , 2009, 34, 1380-1389.	1.3	46
219	Interaction between genetic polymorphisms and stressful life events in first episode depression. <i>Journal of Affective Disorders</i> , 2009, 119, 107-115.	2.0	84
220	Do stressful life events predict medical treatment outcome in first episode of depression?. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2009, 44, 752-760.	1.6	20
221	Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression. <i>Trials</i> , 2009, 10, 66.	0.7	13
222	High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding. <i>NeuroImage</i> , 2009, 46, 360-366.	2.1	50
223	Whole blood BDNF levels in healthy twins discordant for affective disorder: Association to life events and neuroticism. <i>Journal of Affective Disorders</i> , 2008, 108, 165-169.	2.0	30
224	Salivary cortisol in unaffected twins discordant for affective disorder. <i>Psychiatry Research</i> , 2008, 161, 292-301.	1.7	30
225	Measurements of brain-derived neurotrophic factor: Methodological aspects and demographical data. <i>Brain Research Bulletin</i> , 2007, 73, 143-149.	1.4	178
226	Attention to side effects enhances medical adherence. <i>Acta Psychiatrica Scandinavica</i> , 2007, 115, 82-82.	2.2	4
227	Personality traits in unaffected twins discordant for affective disorder. <i>Acta Psychiatrica Scandinavica</i> , 2007, 115, 442-450.	2.2	16
228	Quality of life in unaffected twins discordant for affective disorder. <i>Journal of Affective Disorders</i> , 2007, 99, 133-138.	2.0	4
229	Do personality traits predict first onset in depressive and bipolar disorder?. <i>Nordic Journal of Psychiatry</i> , 2006, 60, 79-88.	0.7	73
230	Cognitive function in unaffected twins discordant for affective disorder. <i>Psychological Medicine</i> , 2006, 36, 1119-1129.	2.7	107
231	Neural responses during down-regulation of negative emotion in patients with recently diagnosed bipolar disorder and their unaffected relatives. <i>Psychological Medicine</i> , 0, , 1-12.	2.7	1
232	Emotional cognition subgroups in unaffected first-degree relatives of patients with mood disorders. <i>Psychological Medicine</i> , 0, , 1-11.	2.7	1
233	Pharmacological Treatment of Individuals at Familial Risk for Bipolar or Major Depressive Disorders: a Scoping Review. <i>Current Treatment Options in Psychiatry</i> , 0, , 1.	0.7	0